A rat study links MK-677 to effort choices

The rat work used a dose-response design. It tested decision-making under conflict, where reward and effort trade off. Only the moderate ibutamoren dose changed cost sensitivity, which means how much effort an animal accepts to get a reward. Low and high doses did not change that measure ¹. This points to a pattern shaped like an upside-down U, where a middle level of receptor activity changes behavior while lower and higher levels do not. The limitation is that the study was done in rats, not people, and the task measures only one narrow type of decision. The cited sources do not include a human trial of that behavioral task.

The same research team traced the neural pathway. They found many ghrelin receptors in dorsomedial striosomes. Ghrelin receptors are docking sites on cells that respond to the hunger hormone ghrelin. Striosomes are small clusters of cells in a brain area that helps weigh competing choices. Moderate ibutamoren activation increased activity in striosomal neurons that project to the lateral habenula. The lateral habenula is a small brain region that acts like a brake on reward circuits. That activation enhanced inactivation of dopamine neurons in the substantia nigra pars compacta, a brain area that makes dopamine and helps control movement and motivation. Chemogenetic manipulation, where scientists use a designer switch to turn specific cells on or off, confirmed that dorsomedial striosomes play a causal role in both the behavioral change and the downstream circuit activity ¹.

This is a new circuit-level finding for ibutamoren. Earlier work had shown that ibutamoren binds to the ghrelin receptor, a protein that responds to the hunger hormone ghrelin, and switches on signals inside cells ³. That receptor is found in brain regions that control appetite, sleep, and stress ⁴. The new study adds a specific group of striosomal cells as a functional measure. It does not alter what is known about growth hormone or IGF-1. It describes a separate behavioral axis.

A separate 2026 scoping review examined MK-677 alongside five other peptides for musculoskeletal recovery and performance ². Peptides are short chains of amino acids, the building blocks of proteins. A scoping review maps what studies exist rather than combining results. The review followed PRISMA guidelines, which are reporting standards for research summaries, and searched PubMed with peptide and tissue terms. Three reviewers screened papers independently, with a third as tiebreaker. The search included BPC-157, thymosin beta-4, CJC-1295, MK-677, ipamorelin, and GHK-Cu combined with bone, fracture, muscle, tendon, ligament, meniscus, and cartilage terms ². Overall, 67 percent of included publications used preclinical animal models ². In those animal models, each compound produced variable effects on tendon, muscle, bone, and ligament healing ². Human clinical studies were few, often lacked robust controls, and showed modest improvements at best for metabolic bone health and degenerative knee pain ².

The limitation is that the review covered six peptides together, so MK-677-specific human data were sparse. It serves as a landscape of what has been studied. For MK-677, that landscape remains mostly preclinical, with no strong human evidence for musculoskeletal recovery.

Older human research established a different, more reproducible outcome set. The table below lays out six studies in order.

Growth hormone and IGF-1 are hormones that help with growth and tissue maintenance. Most of the data lean toward reliable growth hormone and IGF-1 elevation, with modest and inconsistent body composition or functional improvements.

The new brain circuit sits outside that hormone picture. It does not contradict the older findings. It adds a behavioral measure that had not been measured in humans. The rat study used doses that produced behavioral effects only in a middle range, while human endocrine studies used fixed daily doses and did not assess cost sensitivity. No bridge study has connected the two domains.

The evidence cannot yet say whether moderate-dose ibutamoren changes conflict-based decision-making in humans. The rat circuit is plausible but untested in people. The scoping review cannot answer whether MK-677 improves musculoskeletal recovery in rigorous human trials. Existing human data show modest improvements at best in narrow metabolic bone and knee pain contexts ². It is also unknown whether the brain circuit effect appears at doses that raise IGF-1, or whether it interacts with appetite, sleep, or motivation in ways that matter outside a laboratory conflict task.